Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (1128)	9/3/2003 11:01:44 AM
From: scaram(o)uche	Respond to of 1833

SEQUENOM Increases Throughput and Capacity for MassARRAY System Wednesday September 3, 10:52 am ET New Application Note For Increased Multiplexing Now Available SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM - News) today announced a new method for increased multiplexing using the Company's MassARRAY(TM) system. This new method enables customers to analyze up to 15 single nucleotide polymorphisms (SNPs) in an individual reaction using existing MassARRAY hardware and software components. Furthermore, SEQUENOM's assay design software supports the automated design of multiplexed SNP assays without the need for costly and time-consuming optimization or validation. (snip)

To: Tomato who wrote (1128)	9/10/2003 11:03:37 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

>> Where does the spin-off get its money << Dunno. As you know, I don't favor splitting up the cash and the patents/licenses. I favor staying in biotech, finding another company that has an interest in adenosine receptors and/or GPCR. But, if SLV320 is what we're hoping for and if Goddard wasn't blowing bull, it shouldn't be hard to find a little cash to pay the attorneys. Or Newbie Company Inc. could retain an interest in return for paying the patent attorneys and maintenance fees. I haven't gotten any response to my "idea" emails. That's what I like to see from a company, one-way communications. OTOH, she may be deleting them, thinking that they're spam. Frustrating. Yes, I mentioned Broach. Yes, he has the experience to recognize good ops. If we could get Carl's ear and he gave a damn about pocket change like this? He once had a passion for biotech, so it would work. The buyer is still there. Unfortunately, so is a seller. BMY still? I'm getting tired of looking for patent developments and following very old, cold leads ("SmithKline", etc.). They've let this sit until it's silly. Not selling, just disappointed that Icahn doesn't tend to all of his assets.